Heart Bypass Surgery Drug Causing Kidney/Renal Failure Suspended; Anapol Schwartz Attorney -- Representing Victims -- Says Situation Could Be Next Baycol
November 6, 2007 12:26

PHILADELPHIA--(BUSINESS WIRE)--According to Trasylol Lawyer, James Ronca, Esq., of law firm Anapol, Schwartz, Weiss, Cohan, Feldman & Smalley, P.C., Bayer AG?s announcement today that it would suspend sales of blood-clotting drug Trasylol, could lead to a situation in which Trasylol Lawsuits become Bayer's next Baycol. Trasylol is used in coronary artery bypass graft (CABG) procedures and found to cause kidney/renal failure.

Read More: Business Wire

Researchers at Duke University Medical Center found that the incidence of acute kidney failure associated with coronary artery bypass surgery increased almost five-fold during the study period. The researchers estimate that approximately 20,000 cases of the... (Read Article)

Friday-October 13, Bayer AG suspended two senior employees over the company's failure to provide U.S. regulators with data on its heart-surgery drug Trasylol. Bayer also said it had hired an independent counsel to investigate its actions regarding the disclosure... (Read Article)

Failure by the German pharmaceutical giant Bayer to inform the Food and Drug Administration of the disquieting results of a large observational study cannot be easily dismissed with an apology. Circumstances suggest that Bayer sought to hide the results and... (Read Article)

On September 29, 2006, as reported in Yahoo, German-based Bayer acknowledged that it mistakenly did not inform the U.S. Food and Drug Administration about a retrospective study commissioned by the company to analyze the effects of aprotinin, aminocaproic acid,... (Read Article)

On September 29, 2006 German-based Bayer acknowledged that it mistakenly did not inform the U.S. Food and Drug Administration about a retrospective study commissioned by the company to analyze the effects of aprotinin, aminocaproic acid, and tranexamic acid in patients undergoing coronary artery bypass graft (CABG) surgery. This data was not shared immediately with the FDA because it was preliminary in nature and raised significant questions on the study population, outcomes, and methodology. Bayer has submitted a copy of the preliminary Trasylol report to the FDA and has notified other regulatory authorities. (Yahoo)